What Is hsCRP

hsCRP is a blood test that measures C-reactive protein at very low concentrations using a high-sensitivity assay, making it capable of detecting the subtle, chronic inflammation that standard CRP tests miss. C-reactive protein is produced by the liver in response to inflammatory signals, particularly interleukin-6. Because low-grade systemic inflammation is implicated in cardiovascular disease, metabolic dysfunction, and biological aging, hsCRP has become one of the most widely used inflammatory biomarkers in preventive and longevity medicine.

Chronic low-grade inflammation operates below the threshold of symptoms. A person can feel healthy while carrying an elevated inflammatory burden that accelerates arterial plaque formation, insulin resistance, and cellular senescence over years or decades. This process, sometimes called inflammaging, is a central driver of the diseases most responsible for reduced healthspan: heart attack, stroke, type 2 diabetes, and neurodegenerative conditions. hsCRP provides a single, inexpensive, widely available number that captures the aggregate inflammatory signal the body is producing.

From a longevity perspective, hsCRP is valuable because it integrates multiple upstream inputs. Poor sleep, excess visceral fat, periodontal disease, gut permeability, a pro-inflammatory diet, chronic psychological stress, and environmental exposures can all elevate it. This makes hsCRP less a diagnosis and more a compass: it tells you whether your body's inflammatory load is moving in the right direction over time, even when the specific source has not yet been identified. Large epidemiological studies have consistently linked higher hsCRP with increased all-cause mortality, independent of cholesterol levels.

The liver synthesizes C-reactive protein primarily in response to interleukin-6, a cytokine released by immune cells, adipose tissue, and damaged endothelium. When tissues are inflamed (whether from infection, injury, metabolic stress, or autoimmunity), macrophages and other immune cells release IL-6 into the bloodstream, and hepatic CRP production rises within hours. CRP itself functions as part of the innate immune system: it binds to damaged cells and foreign surfaces, activating complement and facilitating phagocytosis.

The standard CRP assay was designed to detect the large spikes that accompany acute illness, typically measuring concentrations above 10 mg/L. The high-sensitivity assay uses immunonephelometry or immunoturbidimetry calibrated to detect concentrations as low as 0.1 to 0.3 mg/L. This precision is what allows hsCRP to differentiate between a person at 0.5 mg/L and one at 2.8 mg/L, a distinction that carries meaningful cardiovascular risk information but would be invisible to a conventional CRP test.

Once measured, hsCRP reflects the total inflammatory output of the body at that moment. It does not identify where the inflammation originates. This is both its strength (it captures the net effect of all inflammatory drivers) and its limitation (an elevated result requires further investigation to determine the source). Because CRP has a relatively short half-life of about 19 hours, levels respond quickly to changes in inflammatory status, making it useful for tracking the effects of interventions over weeks to months.

The hsCRP test measures the concentration of C-reactive protein circulating in the blood, expressed in milligrams per liter (mg/L). C-reactive protein is a pentraxin, a ring-shaped protein assembled in the liver and released into the bloodstream when inflammatory cytokines (primarily interleukin-6) signal that tissue damage or immune activation is occurring somewhere in the body. The protein itself participates in immune defense by opsonizing pathogens and damaged cells for clearance.

What distinguishes the high-sensitivity assay from the standard CRP test is detection range. Standard CRP is calibrated for the large elevations seen in serious infections or autoimmune flares, typically above 10 mg/L. The high-sensitivity assay reliably measures concentrations below 1.0 mg/L, which is the range relevant to chronic, subclinical inflammation. This subclinical zone is where cardiovascular risk stratification occurs and where the slow, persistent inflammatory processes linked to aging reside.

Fasting is not strictly required for hsCRP, but drawing blood in a fasted state (typically morning) reduces variability and makes values more comparable across tests. Avoid testing during or within two weeks of an acute illness, cold, dental procedure, or injury, as these will temporarily spike CRP and obscure the baseline inflammatory picture. Intense exercise in the 24 to 48 hours before the draw can also transiently elevate levels.

If you are tracking hsCRP over time, consistency matters more than perfection. Draw at the same time of day, under similar conditions (fasted or not fasted), and avoid testing during menstruation if you are premenopausal, since hormonal fluctuations can influence CRP production. Inform your ordering provider about any medications you take, as statins, fibrates, and hormonal contraceptives can all influence results.

The American Heart Association and Centers for Disease Control jointly established risk categories for hsCRP in the context of cardiovascular disease: below 1.0 mg/L is considered lower risk, 1.0 to 3.0 mg/L moderate risk, and above 3.0 mg/L higher risk. Values consistently above 10 mg/L generally indicate an acute inflammatory process unrelated to baseline cardiovascular risk and should be investigated separately before the test is used for risk stratification.

These cutoffs, while widely used, are population averages derived primarily from large studies in Western populations. Individual context matters. A lean, physically active person with an hsCRP of 2.5 mg/L warrants a different investigation than a sedentary person with metabolic syndrome and the same number. Practitioners in longevity medicine often aim for values below 1.0 mg/L and ideally below 0.5 mg/L, viewing even modest elevations as a signal worth investigating. The trend over time is generally more informative than any single value, so comparing results across two or more tests gives a clearer picture of your inflammatory trajectory.

For establishing a reliable baseline, two tests separated by at least two weeks are recommended, since a single measurement may catch a transient spike. Once a baseline is confirmed, annual testing is reasonable for individuals with values below 1.0 mg/L and no active inflammatory concerns. Those with elevated levels who are implementing lifestyle changes (dietary shifts, exercise programs, weight loss, sleep interventions) benefit from retesting every three to four months to assess the trajectory.

Clinicians managing cardiovascular risk or chronic inflammatory conditions may test more frequently, particularly when adjusting medications like statins that are expected to lower CRP. There is no upper limit on testing frequency from a safety standpoint, as it requires only a standard blood draw. However, testing too frequently (weekly, for instance) offers little additional information because the interventions that lower hsCRP take weeks to months to produce measurable changes.

hsCRP is among the most studied inflammatory biomarkers in medicine. Large prospective cohort studies involving tens of thousands of participants have demonstrated that elevated hsCRP independently predicts first cardiovascular events, even after adjusting for traditional risk factors like LDL cholesterol, blood pressure, and smoking status. The JUPITER trial, a major randomized controlled trial, showed that statin therapy reduced both hsCRP and cardiovascular events in individuals with elevated hsCRP but normal LDL, which helped establish hsCRP as a clinically actionable marker rather than merely a statistical association.

Beyond cardiovascular disease, observational research has linked higher hsCRP to increased risk of type 2 diabetes, certain cancers, cognitive decline, and all-cause mortality. Several intervention studies have confirmed that weight loss, aerobic exercise, Mediterranean-style diets, and omega-3 supplementation can reduce hsCRP levels, though the magnitude of reduction varies. Gaps remain in understanding whether lowering hsCRP through specific anti-inflammatory agents (beyond statins) directly reduces hard clinical endpoints, or whether the reduction simply reflects improvement in the underlying condition. Additionally, hsCRP values vary by sex, ethnicity, and BMI, and universally applied cutoffs may not carry the same prognostic weight across all populations.

hsCRP is a simple blood draw with negligible physical risk. The main consideration is interpretive: a single elevated result can cause unnecessary anxiety if taken out of context. Acute illness, minor infections, vigorous exercise within the prior 24 to 48 hours, hormonal contraceptives, and obesity can all raise levels independently of cardiovascular pathology. An elevated hsCRP should not be used alone to initiate medication; it is most informative when interpreted alongside lipid markers, metabolic panels, and clinical history. Population-level cutoffs may not apply equally to all demographic groups, so working with a clinician familiar with this nuance is worthwhile for accurate interpretation.